Tuesday 16 June 2015, Amsterdam
The report recognizes the following companies as the key players in the global depression drugs market: Actavis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline and Pfizer
Other Prominent Vendors in the market are: Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals and Valeant Pharmaceuticals
Commenting on the report, an analyst said: “Growing public awareness about depression is expected to increase the acceptability of various drugs. The Anxiety and Depression Association of America, Mental Health America, Depression and Bipolar Support Alliance, Suicide Awareness, Voices of Education, and Freedom from Fear are non-profit organizations involved in spreading awareness of depression and its implications.”
According to the report, WHO has described depression as one of the most disabling illnesses worldwide. In 2012, it was estimated that more than 18 million people suffered from depression in the US, affecting about 25% of women and 10% of men. According to the CDC, about one in every 10 individuals in the US suffers from depression. The prevalence rate of depression is very high because of factors such as genetic vulnerability, lack of proper diagnosis and treatment, and a high degree of association with other medical disorders such as diabetes, stroke, cardiovascular diseases, and psychiatric disorders.
Further, the report states that the expiry of patents of major branded drugs is expected to lead to the erosion of their market share and a fall in revenue.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.